Companies › Can-Fite BioPharma
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Namodenoson (CF102) Adenosine A3 receptor agonist | ADORA3 | Phase 3 | Hepatocellular Carcinoma; Pancreatic Adenocarcinoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05201404 | Namodenoson (CF102) | Phase 3 | Hepatocellular Carcinoma | Oncology | Feb 2026 |
| NCT06387342 | Namodenoson (CF102) | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
Cash and short-term investments of $6m on 2025-12-31; operating cash outflow about $9m a year; runway about 7 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
LeonaBio RenovoRx Intensity Therapeutics Angiodynamics iTeos Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.